Therapeutic Applications

Therapeutic Applications

ALS

Genervon's scientists confirmed the mechanism of action (MOA) of ALS. GM604 controls over 4,000 genes, and modifies ALS disease progression by modulating 8 or more pathways involving up to 22 biologic functions concurrently and dynamically: 1. Insulin Receptor binding for ALS therapeutic effects. 2. Free Radical damages reduction for inhibition of ALS apoptosis. 3. PIP3 Kinase Activation for neuroprotection against ALS. 4. Bax inhibition reduced neuron death caused by ALS. 5. Akt activation to suppress SOD1 expression which caused ALS disorder. 6. Hypoxic response normalization to prevent ALS degeneration. 7. DNA repair capability increase against ALS neuron apoptosis. 8. Axonal transport stimulation to delay ALS onset

GM604 also proved to be quite effective in the disease modification of ALS in ALS animals with mutant SOD1. It led to an improved clinical score in SOD1 mice (p<0.001 for all groups compared to control). Moreover, GM604 delayed the onset of ALS symptoms by 27%, extended life by 30% and delayed the median clinical score deterioration time in ALS mice by 41%.

GM604 also provided neuroprotection against soluble inflammatory factors from ALS human patients' Cerebral Spinal Fluid (CSF) in vitro by 175%. GM604 dramatically increased the survival life span by 500% (6 fold from 7-14 weeks to 55-65 weeks) and increased of preservation of motor neurons by 160% (2.6 fold) in a Wobbler Mice Model for motoneuron diseases such as ALS.

The design of optimal therapeutics by discovery of endogenous embryonic stage human master regulators is changing from hitting single pathways to a more comprehensive and dynamic approach addressing the complexity of neuro-degenerative disease. Genervon has a family of highly specific drug candidates that addresses this complexity, and believes it is at the forefront of a shift that is only beginning to be appreciated.

Acute Ischemic Stroke

Stroke is the third leading cause of death in the United States, affecting approximately 700,000 people per year. The estimated cost to the healthcare system is $73 billion annually. Approximately 80% of strokes are ischemic. Ischemic strokes are caused by a blockage of the blood flow to the brain. This may be caused by a number of factors, including a blood clot or narrowing of the arteries due to build up of fatty material. The molecular chain of events following an ischemic stroke is a multifactorial process involving multiple signaling pathways. The ideal stroke therapeutic would target multiple parts of this cascade and have anti-inflammatory, anti-apoptotic and anti-oxidant properties. Previous clinical attempts to develop drugs for stroke through targeting single specific processes, such as free radical scavengers (Cerovive; Renovis) or NMDA antagonism (Cerestat; Boehringer Ingelheim), have not been successful. Currently only one FDA-approved ischemic stroke therapeutic is on the market, Activase (Genentech). This drug works by degrading the clot and has no direct impact on other pathological processes associated with the ischemia. In addition, its use is limited to administration within three hours of the incidence of the stroke, leading to only 4% of acute stroke patients receiving the drug.

GM6 and Stroke

Through in vitro and in vivo studies, GM6 has demonstrated its ability to affect the expression of numerous genes, including those involved in neurogenesis, neural development and neural signaling. These findings indicate that GM6 may function as a master switch that signals through multiple neural pathways, such as PI3 kinase.

In a study published in Brain Research, GM6 demonstrated its ability to exert neuroprotective effects in a mouse model of stroke. In this study, GM6 was found to increase neurogenesis as well as decrease apotosis and inflammation in the mouse brain. In addition, GM6 was able to penetrate the blood-brain barrier.

Further research has also found that GM6 induces the expression of anti-inflammatory, anti-apoptotic and anti-oxidant proteins. These are important neuroprotective proteins with application for the treatment of acute ischemic stroke.

GM6 Has Additional Applications

Due to its neurologically active properties, Genervon is also conducting preclinical research exploring the use of GM6 to treat other neurological disorders. In a variety of in vitro and in vivo models, GM6 has shown neuroregenerative and neuroprotective properties. MNTF has been shown to have neuroprotective and anti-apoptotic properties as well and may play a role in stem cell differentiation into motoneurons.

These findings indicate that GM6 is a promising treatment for Parkinson’s disease, Alzheimer’s disease, spinal cord injuries, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and Huntington’s disease.


 
Copyright © 2017 Genervon Biopharmaceuticals, LLC. All rights reserved. All other trademarks or trade names are the property of their respective holders.